StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) stock

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.53+0.67 (+4.51%)

Close on Nov 18, 2026Market cap $708.96MP/E –Yield –

Attovia Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.02M–
Q2 FY2026Jun 30, 2026-$21.80M–
Q3 FY2025Sep 30, 2025-$15.60M–
Q2 FY2025Jun 30, 2025-$16.62M–

More Attovia Therapeutics figures

See a number that looks wrong?